Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19
APUS•Assignment and transfer agreement with Freet
Apimeds Pharmaceuticals US Inc. said in an SEC filing that it entered into an assignment and transfer agreement with Freet on Aug. 19, 2026.
- Freet assigns all Apitox-related rights to Apimeds Pharmaceuticals.
- Apimeds receives 100% Korean clinic rights, 25% U.S. royalty, and 25% overseas revenue participation for Apitox.
- The assigned rights are free and clear of prior claims or encumbrances.
